Weekly Roundup 24 Nov 2023 Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA …an antibody that was discovered based on WuXi Bio’s integrated technology platforms, so that Myricx can develop an ADC using the antibody, to target solid tumors, through its NMT-1 platform…. November 24, 2023 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Oct 2025 Seven of the top biotech companies to know about in South San Francisco …and other CNS disorders. Vistagen’s pipeline includes five clinical-stage product candidates, including its lead candidate fasedienol. Each candidate is an investigational agent belonging to a new class of drugs known… October 21, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Oct 2024 Six biotech companies advancing multiple sclerosis therapies …debilitating disease. Table of contents Biogen Leading multiple sclerosis drug candidate of Biogen: BIIB091 Biogen is known for its pioneering work in the neuroscience field. It has been discovering and… October 24, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 May 2025 Interleukin therapeutics: 9 companies to follow in 2025 …for ANK-101 at the AACR Annual Meeting Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of cytokine-based treatments. The company’s lead candidate, ANK-101 (tolododekin… May 27, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 22 Dec 2022 10 biotech companies to watch in 2023 …candidates — called TCR-T cell therapies — are designed to tackle solid cancers. This is because they are genetically modified to express a custom version of a T-cell protein called… December 22, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Oct 2025 The 11 most advanced microbiome players aiming for the gut …Adelaide, Australia Founded: 2018 Lead candidate: BB265 BiomeBank is a clinical-stage biotech developing microbiome therapeutics that restore gut microbial ecology. The company combines a first-generation donor-derived product with a second-generation, co-cultured… October 28, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Jul 2025 Which biotech companies are gaining traction in genetic diseases? …to advance treatments for genetic diseases. Table of contents Actio Biosciences Headquarters: San Diego, U.S.A. Latest funding round: $66 million series B (June 2025) Lead candidates: ABS‑1230 for KCNT1-related epilepsy;… July 24, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 5 Nov 2025 Novo Nordisk’s pipeline plan: How the pharma giant is refocusing amid major restructuring …appointment in July, cutting several pipeline drugs (including two obesity candidates), laying off 9,000 employees in an attempt to save around 8 billion Danish kroner ($1.3 billion) per year by… November 5, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 30 Apr 2018 Record Series B Financing Supports Antibody Cancer Therapy …of antibody-based therapies for cancer has recently been on the rise in European biotech. For example, late last year Argenx raised €195M to support the clinical development of its antibody… April 30, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jun 2020 Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle Update (04/06/2020): After upholding four of Kymab’s patents addressing the production of antibody drugs earlier this year, the US Patent Trial and Appeal Board has rejected Regeneron’s attempt to invalidate… June 4, 2020 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 German Biotech Enters the Clinic with Next-Generation Antibody for AML …immunotherapy candidate, TacSyn, to treat patients at a stage of existing disease of AML as well as acute lymphoblastic leukemia (ALL). This bispecific antibody contains an anti-CD3 domain, which is… May 31, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2017 The EU Approves New Treatment for a Rare Pediatric Cancer …Human Use (CHMP) has now given a positive opinion on APN311, recommending the approval of the new drug. APN311 is a monoclonal antibody targeting the neuroblastoma-specific antigen GD2. The antibody… May 8, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email